#1 Clinical Trials Search in Europe

Darolutamide

Darolutamide, a novel androgen receptor inhibitor, is being extensively studied in clinical trials for various types of cancer, particularly prostate cancer. These trials aim to evaluate its efficacy, safety, and potential combinations with other treatments to improve outcomes for patients with different stages of cancer. This article summarizes key findings from recent clinical trials investigating darolutamide.

Table of Contents

What is Darolutamide?

Darolutamide is a medication used in the treatment of prostate cancer. It is known by several names, including ODM-201, BAY 1841788, and NUBEQA[1]. Darolutamide belongs to a class of drugs called androgen receptor antagonists or inhibitors. These medications work by blocking the effects of male hormones (androgens) in the body, which can help slow down or stop the growth of prostate cancer cells[2].

How Darolutamide Works

Darolutamide works by targeting and blocking the androgen receptor (AR) in prostate cancer cells. The androgen receptor is a protein that, when activated by male hormones like testosterone, can promote the growth and spread of prostate cancer. By blocking this receptor, Darolutamide helps to slow down or stop the progression of prostate cancer[2].

One unique feature of Darolutamide is its ability to penetrate the blood-brain barrier (a protective barrier that separates the brain from the bloodstream) to a lesser extent compared to similar medications. This characteristic may result in fewer side effects related to the central nervous system[3].

Conditions Treated with Darolutamide

Darolutamide is primarily used to treat various stages of prostate cancer, including:

  • Non-metastatic castration-resistant prostate cancer (nmCRPC): This is a type of prostate cancer that has not spread beyond the prostate gland but has become resistant to hormone therapy that lowers testosterone levels[1].
  • Metastatic hormone-sensitive prostate cancer (mHSPC): This refers to prostate cancer that has spread to other parts of the body but still responds to treatments that lower testosterone levels[4].
  • Metastatic castration-resistant prostate cancer (mCRPC): This is an advanced form of prostate cancer that has spread beyond the prostate and no longer responds to treatments that lower testosterone levels[5].

Additionally, research is being conducted to explore the potential use of Darolutamide in other conditions, such as breast cancer and salivary gland cancer[2][6].

How Darolutamide is Administered

Darolutamide is typically administered orally in the form of tablets. The usual dosage is 600 mg (two 300 mg tablets) taken twice daily, for a total daily dose of 1200 mg[4]. It is recommended to take Darolutamide with food to improve absorption[2].

The duration of treatment can vary depending on the specific condition being treated and the individual patient’s response. In some clinical trials, treatment durations of up to 24 months have been studied[7].

Darolutamide in Combination Therapies

Darolutamide is often used in combination with other treatments to enhance its effectiveness. Some common combination therapies include:

  • Androgen Deprivation Therapy (ADT): This is a hormone therapy that reduces testosterone levels in the body. Darolutamide is frequently used alongside ADT to provide a more comprehensive approach to blocking the effects of male hormones on prostate cancer cells[4].
  • Radiotherapy: Some clinical trials are investigating the combination of Darolutamide with radiation therapy to treat prostate cancer that has spread to nearby lymph nodes[7].
  • Radium-223: This is a radioactive medication used to treat prostate cancer that has spread to the bones. Research is ongoing to evaluate the combination of Darolutamide with Radium-223[8].
  • Other targeted therapies: Studies are exploring combinations of Darolutamide with other medications that target specific pathways involved in cancer growth, such as PI3K/mTOR inhibitors like Gedatolisib[5].

Potential Side Effects

While Darolutamide is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Fatigue
  • Weakness
  • Joint pain
  • Hot flashes
  • Decreased appetite

It’s important to note that Darolutamide may have fewer central nervous system-related side effects compared to similar medications due to its limited ability to cross the blood-brain barrier[3]. However, as with any medication, patients should report any unusual or severe side effects to their healthcare provider.

Ongoing Research and Future Directions

Darolutamide continues to be the subject of numerous clinical trials aimed at expanding its use and understanding its effects. Some areas of ongoing research include:

  • Evaluating Darolutamide in earlier stages of prostate cancer[9]
  • Investigating intermittent dosing schedules to potentially reduce side effects while maintaining efficacy[4]
  • Exploring combinations with other cancer treatments to enhance overall effectiveness[8][5]
  • Assessing the potential use of Darolutamide in other types of cancer, such as breast cancer and salivary gland cancer[2][6]
  • Studying the long-term effects of Darolutamide on testosterone recovery after treatment[1]

As research progresses, our understanding of Darolutamide’s potential benefits and optimal use in cancer treatment continues to evolve. Patients interested in learning more about ongoing clinical trials involving Darolutamide should discuss options with their healthcare provider.

Aspect Details
Main Cancer Types Prostate cancer (various stages), breast cancer, salivary gland cancer
Common Combinations ADT, radiotherapy, radium-223, docetaxel, gedatolisib
Dosage 600 mg twice daily (1200 mg total daily dose)
Administration Oral tablets, typically with food
Key Outcomes Measured rPFS, OS, PSA response, quality of life, safety profile
Novel Approaches Intermittent dosing, combination with novel drugs, use in non-prostate cancers
Patient Populations Metastatic and non-metastatic CRPC, hormone-sensitive prostate cancer, AR-positive cancers

FAQ

  • What is darolutamide and how does it work? Darolutamide is a novel androgen receptor inhibitor that blocks the effects of male hormones (androgens) in cancer cells. It works by preventing androgens from binding to their receptors, which can slow down or stop the growth of certain types of cancer, particularly prostate cancer.
  • In which types of cancer is darolutamide being studied? Darolutamide is primarily being studied in prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer, and metastatic hormone-sensitive prostate cancer. It is also being investigated in breast cancer and salivary gland cancer.
  • How is darolutamide administered in clinical trials? In most trials, darolutamide is administered orally as tablets. The typical dose is 600 mg (two 300 mg tablets) taken twice daily, for a total daily dose of 1200 mg. It is often recommended to be taken with food.
  • What are some common combinations being studied with darolutamide? Darolutamide is being studied in combination with various treatments, including androgen deprivation therapy (ADT), radiotherapy, radium-223, docetaxel, and other novel drugs like gedatolisib. These combinations aim to enhance the overall effectiveness of cancer treatment.
  • What are the main outcomes being measured in darolutamide clinical trials? The main outcomes being measured include radiographic progression-free survival (rPFS), overall survival (OS), time to pain progression, PSA response, quality of life, and safety profiles. Some trials also focus on specific outcomes like testosterone recovery or the effect on breast cancer tissue.

Ongoing Clinical Trials on Darolutamide

  • A study testing tulmimetostat with darolutamide or abiraterone in patients with metastatic hormone-sensitive prostate cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Hungary Italy Spain

  • Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Darolutamide for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Sweden

  • Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Hungary +5

  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Ireland Italy The Netherlands Spain

  • Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Ireland Spain

  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

Glossary

  • Androgen Receptor (AR): A protein in cells that androgens (male hormones) bind to, which can stimulate the growth of prostate cancer cells.
  • Androgen Deprivation Therapy (ADT): A treatment that reduces levels of male hormones in the body, used to slow the growth of prostate cancer.
  • Castration-Resistant Prostate Cancer (CRPC): Prostate cancer that continues to grow despite low levels of testosterone in the body.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland; elevated levels may indicate prostate cancer.
  • Radiographic Progression-Free Survival (rPFS): The time from treatment start until cancer progression is detected on imaging scans or death occurs.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure cancer response in clinical trials.
  • Neoadjuvant Therapy: Treatment given before the main treatment, often to shrink a tumor before surgery.
  • Gonadotropin-Releasing Hormone (GnRH) Antagonist: A type of drug that blocks the production of hormones that stimulate testosterone production.
  • Stereotactic Ablative Body Radiotherapy (SABR): A highly precise form of radiation therapy that delivers high doses of radiation to specific areas of the body.

References

  1. https://clinicaltrials.gov/study/NCT06463457
  2. https://clinicaltrials.gov/study/NCT03004534
  3. https://clinicaltrials.gov/study/NCT03704519
  4. https://clinicaltrials.gov/study/NCT06177015
  5. https://clinicaltrials.eu/trial/study-of-gedatolisib-and-darolutamide-for-patients-with-metastatic-castration-resistant-prostate-cancer/
  6. https://clinicaltrials.gov/study/NCT05694819
  7. https://clinicaltrials.eu/trial/study-on-darolutamide-triptorelin-and-leuprorelin-acetate-for-patients-with-newly-diagnosed-prostate-cancer-and-pelvic-lymph-node-metastases/
  8. https://clinicaltrials.gov/study/NCT05771896
  9. https://clinicaltrials.gov/study/NCT06029036